PT-141 (Bremelanotide)
Also known as Bremelanotide
PT-141, known by the generic name bremelanotide, is a synthetic peptide derived from the melanocortin hormone alpha-MSH. It is studied primarily for its effects on sexual desire and arousal, acting through the central nervous system rather than the vascular pathways targeted by other therapies for sexual dysfunction. Bremelanotide received FDA approval under the brand name Vyleesi for premenopausal women with acquired, generalized hypoactive sexual desire disorder. Outside of its approved indication, it has drawn research and off-label interest for use in men, though this application is less established. As with any compound affecting hormonal and neurological pathways, individual response varies and effects are not guaranteed.
Reported benefits
- Studied for supporting sexual desire and arousal in individuals with hypoactive sexual desire disorder
- Acts via central nervous system pathways rather than vascular mechanisms
- FDA-approved formulation (Vyleesi) available with established clinical trial data
- Effects reported to occur within a few hours of administration in clinical studies
- May be considered when vascular-targeted therapies are not appropriate, per a prescriber's guidance
How it works
Bremelanotide acts as a non-selective agonist at melanocortin receptors, with particular affinity for MC3R and MC4R subtypes in the hypothalamus. Activation of these receptors is believed to modulate dopaminergic pathways associated with sexual motivation and arousal. Unlike PDE5 inhibitors, its mechanism does not depend primarily on vascular blood flow, which is why it is studied for desire-based rather than purely physiological sexual dysfunction.
Dosing ranges
| Tier | Dose | Frequency |
|---|---|---|
| Low | 500 mcg | as needed, no more than once daily |
| Moderate | 1,000 mcg | as needed, no more than once daily |
| High | 1,750 mcg | as needed, no more than once daily |
Estimate your dose
Dose estimator
Educational estimate for PT-141 (Bremelanotide), scaled to body size. Not medical advice.
Read before using
This tool produces a rough, educational estimate by scaling commonly-published research ranges to lean body mass. It is not a prescription, medical advice, or a substitute for a licensed clinician. Most peptides use fixed dosing, not weight-based dosing. Individual needs vary. You are solely responsible for how you use this information.
Mixing & syringe units
Target dose follows the estimate above. Change it there, or edit it directly below.
Reconstitution calculator
How much water to add and how many insulin-syringe units to draw for PT-141 (Bremelanotide). Educational only.
Draw to this mark
20units
= 0.2 mL for a 1,000 mcg dose
Concentration
5,000 mcg/mL
Doses per vial
10
A U-100 syringe reads 100 units per mL. This is a reconstitution math helper only, not a prescription or dosing advice. Verify every calculation and consult a qualified healthcare provider.
Possible side effects
Stacking notes
Some discussions in research literature note potential interaction with medications affecting blood pressure or heart rate; combining with other melanocortin-pathway compounds is not well studied and should be approached cautiously.
Common protocols
Common questions
What is PT-141 (Bremelanotide) used for?
PT-141, known by the generic name bremelanotide, is a synthetic peptide derived from the melanocortin hormone alpha-MSH. It is studied primarily for its effects on sexual desire and arousal, acting through the central nervous system rather than the vascular pathways targeted by other therapies for sexual dysfunction. Bremelanotide received FDA approval under the brand name Vyleesi for premenopausal women with acquired, generalized hypoactive sexual desire disorder. Outside of its approved indication, it has drawn research and off-label interest for use in men, though this application is less established. As with any compound affecting hormonal and neurological pathways, individual response varies and effects are not guaranteed. Reported benefits include studied for supporting sexual desire and arousal in individuals with hypoactive sexual desire disorder, acts via central nervous system pathways rather than vascular mechanisms, fda-approved formulation (vyleesi) available with established clinical trial data.
What is a typical PT-141 (Bremelanotide) dose?
Reported ranges run 500-1,750 mcg. A low protocol is 500 mcg as needed, no more than once daily, and a high protocol is 1,750 mcg as needed, no more than once daily. This is reference information, not a dosing recommendation.
What is the half life of PT-141 (Bremelanotide)?
Approximately 2 to 3 hours, based on published pharmacokinetic data.. That is what sets the dosing frequency, and it is why the timing guidance is ~45 min before activity.
How is PT-141 (Bremelanotide) administered?
Subcutaneous: into fat, under the skin.
How long is a PT-141 (Bremelanotide) cycle?
Used on an as-needed basis rather than a continuous daily cycle on, followed by No mandatory off period beyond spacing individual doses at least 24 hours apart off. Clinical labeling suggests limiting use to roughly 8 doses per month; consult a prescriber for guidance specific to individual health status.
What are the side effects of PT-141 (Bremelanotide)?
Reported side effects include nausea, reported as the most common effect in clinical trials, flushing and headache, transient increases in blood pressure and decreased heart rate, injection site reactions, hyperpigmentation of skin or gums with repeated use. Evidence level for this compound is well studied.
Partner offer · $20 off
When did you last
check your blood work?
Regular blood work catches changes early. At-home collection with free pickup, 50+ biomarkers, and results in 72 hours.
- 1Order your kitTakes two minutes online, $20 off with this link.
- 2Collect at homePainless draw with free home pickup, no lab visit.
- 3Results in 72 hours50+ biomarkers with clear optimal ranges.
Partner offer · opens rythm.health
Educational use only, not medical advice. This profile is provided for research and educational purposes. PT-141 (Bremelanotide) may be a research compound or a prescription medication; nothing here is intended to diagnose, treat, cure, or prevent any disease. Dosing figures reflect commonly-published research ranges, not a prescription. Consult a qualified healthcare provider before making any health decision. Read the full disclaimer →